198
Participants
Start Date
October 14, 2019
Primary Completion Date
June 9, 2021
Study Completion Date
June 9, 2021
Placebo IV infusion
Study drug will be initiated at a starting dose of 0.5 ng/kg/min up to 2.0 ng/kg/min. Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line.
Iloprost Injection, for intravenous use
Study drug will be initiated at a starting dose of 0.5 ng/kg/min up to 2.0 ng/kg/min. Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line.
Hospital for Special Surgery, New York
Columbia University Medical Center, New York
University of Pittsburgh Medical Center, Pittsburgh
University of Pennsylvania, Philadelphia
Georgetown University Medical Center - Department of Rheumatology, Washington D.C.
Johns Hopkins University School of Medicine, Baltimore
Medical University of South Carolina (MUSC), Charleston
Ohio State University, Columbus
The University of Toledo Medical Center (UTMC) - Ruppert Health Center, Toledo
Cleveland Clinic, Cleveland
University of Cincinnati - Scleroderma Center, Cincinnati
West Michigan Rheumatology PLLC, Grand Rapids
Froedtert Hospital and the Medical College of Wisconsin, Milwaukee
University of Minnesota Maple Grove, Minneapolis
Northwestern Medical Faculty Foundation, Chicago
University of Nebraska Medical Center, Omaha
University Medical Center New Orleans, New Orleans
University of Texas Houston - Division of Rheumatology and Clinical Immunogenetics, Houston
University of Utah, Salt Lake City
Arizona Arthritis & Rheumatology Research, PLLC, Phoenix
Mayo Clinic - Scottsdale, Scottsdale
University of Arizona - Arthritis Research Center, Tucson
Cedars-Sinai Medical Center, Los Angeles
University of California, Los Angeles Medical Center, Los Angeles
University of California San Francisco, San Francisco
Stanford University Medical Center, Palo Alto
Virginia Mason Medical Center, Seattle
Tufts Medical Center, Boston
University of Michigan, Ann Arbor
Robert Wood Johnson Medical School, New Brunswick
Lead Sponsor
Civi Biopharma, Inc.
INDUSTRY